TATA Health International Holdings Limited
TATA 健 康 國 際 控 股 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

FURTHER DELAY IN PUBLICATION OF THE 2024 INTERIM RESULTS, THE 2024 ANNUAL RESULTS AND THE 2025 INTERIM RESULTS AND FURTHER DELAY IN DESPATCH OF THE 2024 INTERIM REPORT, THE 2024 ANNUAL REPORT AND THE 2025 INTERIM REPORT AND DATES OF BOARD MEETING AND CONTINUED SUSPENSION OF TRADING

Reference is made to the announcement made by the board (the "**Board**") of directors ("**Director(s)**") of TATA Health International Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") dated 3 September 2025 (the "**Announcement**") in relation to, among others, further delay in publication of the Group's interim results for the six months ended 30 June 2024 (the "**2024 Interim Results**") and the despatch of the Group's interim report for the six months ended 30 June 2024 (the "**2024 Interim Report**"). Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Announcement.

FURTHER DELAY IN PUBLICATION OF THE 2024 INTERIM RESULTS, THE 2024 ANNUAL RESULTS AND THE 2025 INTERIM RESULTS AND FURTHER DELAY IN DESPATCH OF THE 2024 INTERIM REPORT, THE 2024 ANNUAL REPORT AND THE 2025 INTERIM REPORT

The Board wishes to inform the shareholders of the Company that there will be a further delay in publication of the 2024 Interim Results, the 2024 Annual Results and the 2025 Interim Results and the despatch of the 2024 Interim Report, the 2024 Annual Report and the 2025 Interim Report as the Company is in the course of finalising the contents of the 2024 Interim Results, the 2024 Annual Results and the 2025 Interim Results. It is expected that the dates of publication of (i) the 2024 Interim Results will be postponed to a date on or before 22 September 2025, (ii) the 2024 Annual Results will be postponed to a date on or before 24 September 2025, and (iii) the 2025 Interim Results will be postponed to a date on or before 26 September 2025.

DATES OF BOARD MEETING

The Board hereby announces that a meeting of the Board will be held on 22 September 2025 (Monday) for the purposes of, among other matters, considering and approving the 2024 Interim Results, and considering the recommendation of an interim dividend, if any.

The Board further announces that a meeting of the Board will be held on 24 September 2025 (Wednesday) for the purposes of, among other matters, considering and approving the 2024 Annual Results, and considering the recommendation of a final dividend, if any.

The Board also announces that a meeting of the Board will be held on 26 September 2025 (Friday) for the purposes of, among other matters, considering and approving the 2025 Interim Results, and considering the recommendation of an interim dividend, if any.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 2 April 2024 and will remain suspended pending the fulfilment of the resumption guidance. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

Shareholders and potential investors of the Company are advised to invest cautiously and to be aware of the investment risks.

By Order of the Board
TATA Health International Holdings Limited
Zhang Ming Qi
Non-executive Director

Hong Kong, 15 September 2025

As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Chu Chun Ho, Dominic, Mr. Zhang Ming Qi and Mr. Chen Qi; and three independent non-executive Directors, namely, Ms. Huang Lin, Mr. Li Liang and Mr. Du Jianfeng.